Abstract
In the treatment of osteoporosis, the tolerance of oral bisphosphonates is often low. The high potency of ibandronate allows iv bolus injections that can be repeated every 2 to 3 months. However, the best dose and time interval of the treatment with iv ibandronate is still debated. Efficacy of 2-mg ibandronate injected every 3 months was tested in men with osteoporosis over 2 yr, in a prospective, open study. Fourteen men with primary osteoporosis, mean age 57±12 yr (range: 40–73), received 2-mg ibandronate iv every 3 months over 2 yr. All got 1 g/day calcium and 880 UI/day vitamin D for 2 yr. Bone mineral density (BMD) increased after 2 yr by 6.7±1.5% (mean change±SEM) at lumbar spine (p<0.001), by 3.2±08% at trochanter (p<0.001) and by 1.4±1.1% at femoral neck (ns). Serum ß-crosslaps and osteocalcin decreased significantly by 30–45 and 30%, respectively, during the 2 yr of treatment. Serum calcium increased from the lower to the middle tertile of the normal range during the 2 yr of the study. The observed decrease of bone remodelling and the increase of BMD are of the same magnitude as those described with oral bisphosphonates. The increase of plasma calcium confirms the positive effect of the supplementation with calcium and vitamin D. These results suggest that 3 months are a good interval between two doses of iv ibandronate, when 2 mg are given.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a word-wide projection. Osteoporos Int 1992, 2: 285–9.
O’Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996, 11: 1010–8.
Eastell R, Boyle IT, Compston J, et al. Management of male osteoporosis: report of the UK Consensus Group. QJM 1998, 91: 71–92.
Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343: 604–10.
De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D. Esophagitis associated with the use of alendronate. N Engl J Med 1996, 335: 1016–21.
Thiebaud D, Burckhardt P, Melchior J, et al. Two years’ effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 1994, 4: 76–83.
Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997, 103: 298–307.
Ralston SH, Thiebaud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997, 75: 295–300.
Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001, 16: 1871–8.
Gluer CC, Blake G, Lu Y, Blunt BA, Jergas M, Genant HK. Accurate assessment of precision error: how to measure the reproducibility of bone densitometry techniques. Osteoporos Int 1995, 4: 262–70.
Garnero P, Grimaux M, Demiaux B, Delmas PD. Measurement of serum osteocalcin with a human specific two-site radioimmunoassay. J Bone Miner Res 1992, 7: 1389–97.
Kaufmann Didisheim N. Définition de l’intervalle de référence de la calcémie dans une population hospitalière. Doctor’s thesis, Faculty of medicine, University of Lausanne, Switzerland, 1989.
Pols HAP, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomised trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999, 9: 461–8.
Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomised controlled trial. JAMA 1999, 282: 1344–52.
Ravn P, Neugebauer G, Christiansen C. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone 2002, 30: 320–4.
Adami S, Delmas P, Felsenberg D, et al. Three-monthly 2 mg intravenous ibandronate bolus injections significantly increase BMD in women with postmenopausal osteoporosis. IOF World Congress of Osteoporosis, Lisbon, Portugal, 2002, p S14–5 (abstract).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lamy, O., Sandini, L., Pache, I. et al. Intravenous ibandronate in men with osteoporosis: An open pilot study over 2 years. J Endocrinol Invest 26, 728–732 (2003). https://doi.org/10.1007/BF03347354
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03347354